Multicenter Phase II Study of Oral Idarubicin in Treated and Untreated Patients with B-Chronic Lymphocytic Leukemia

References

• Arcamone F., Bernardi L., Giardino P., Patelli B., DiMarco A., Casazza A.M., Pratesi G., Reggiani P. Synthesis and anti-tumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin and their beta anomers. Cancer Treat Rep 1976; 60(7)829–34
   PubMedGoogle Scholar
• DiMarco A., Casazza A.M., Pratesi G. Antitumor activity of 4-demethoxydaunorubucin administered orally. Cancer Treat Rep 1977; 61(5)893–94
   PubMedGoogle Scholar
• Harusseau J.L., Pignon B., Reiffers J., Rigal-Huguet F., Cahn J.Y., Le P.Y. Toxicity profile of idarubicin with oral and intravenous idarubicin in the treatment of leukemia. Hematology and Blood Transfusion: Acute Leukemias-Pharmacokinetics, W. Hiddemann. Springer Verlag, Berlin 1992; 625–631
   Google Scholar
• Broggini M., Italia C., Colombo T., Marmonti L., Donelli M.G. Activity and distribution of intravenous and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984; 68(5)739–47
   PubMedGoogle Scholar
• Casazza A.M. Experimental evaluation of anthracycline analogues. Cancer Treat Rep 1979; 63(5)835–44
   PubMedGoogle Scholar
• Casazza A.M., Pratesi G., Giuliani F., DiMarco A. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 1980; 66(5)549–44
   PubMed Web of Science ®Google Scholar
• Casazza A.M., Bertazzoli C., Pratesi G., Bellini O., DiMarco A. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin. Proc Am Assoc Cancer Res 1979; 20: 16
   Web of Science ®Google Scholar
• Casazza A.M., DiMarco A., Bonnadonna G., Bonfante V., Bertazzoli C., Bellini O., Pratesi G., Sala L., Ballerini L. Effects of modification in position 4 of chromophore or in the position 4′ of the aminosugar on the antitumor activity of anthracyclines. Anthracyclines: current status and new development, S.T. Crooke, S.D. Reich. academic press, New York 1980; 430
   Google Scholar
• Bermann E., Wittes R.E., Leyland-Jones B. Phase I clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983; 43: 6096
   PubMed Web of Science ®Google Scholar
• Bonfante V., Ferrai L., Villani F., Bonadonna G. Phase I study of 4-demethoxydaunorubicin. Invest New Drugs 1983; 1(2)161–8
   PubMedGoogle Scholar
• DiMarco A., Zunino F., Casazza A.M. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 1978; 23: 12–20
   PubMedGoogle Scholar
• Zaniboni A., Bolognesi A., Arnoldi E., Tabiadon D., Barni S., Intini C. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anticancer Drugs 1998; 9(4)295–9
   PubMed Web of Science ®Google Scholar
• Barnadas A., Mendiola C., Casado A., Villar A., Jimeno J., Clerigue M., Rosell R., Diaz-Rubio E., Cortes-Funes H., Garcia de Paredes M. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer 1997; 33(2)312–5
   PubMed Web of Science ®Google Scholar
• Elbaek K., Ebbehoj E., Jakobsen A., Juul P., Rasmussen S.N., Bastholt L., Dalmark M., Steiness E. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. Clin Pharmacol Ther 1989; 45(6)627–34
   PubMed Web of Science ®Google Scholar
• Ruutu T., Almqvist A., Hallman H., Honkanen T., Jarvenpaa E., Jarventie G., Koistinen P., Koivunen E., Lahtinen R., Lehtinen M. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish leukemia group. Leukemia 1994; 8(1)11–15
   PubMed Web of Science ®Google Scholar
• Kusnierz-Glaz C.R., Normann D., Weinberg R., Fuchs R., Flasshove M., Hiddemann W., van de Loo J., Buchner T. Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 1993; 11(2)73–80
   PubMed Web of Science ®Google Scholar
• Robert J., Rigal-Huguet F., Harousseau J.L., Pris J., Huet S., Reiffers J., Hurtelopu P., Tamassia V. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Leukemia Res 1987; 11: 961–964
   PubMed Web of Science ®Google Scholar
• Cook G., Sharp R.A., Tansey P., Franklin I.M. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Brit J Haematol 1996; 93: 931–934
   PubMed Web of Science ®Google Scholar
• Steward W.P., Smith D.B., Crowther D. Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma. Ann Oncol 1991; 2(8)605–6
   PubMed Web of Science ®Google Scholar
• Errante D., Sorio R., Zagonel V., Carbone A., Monfardini S., Tirelli U. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14(3)243–5
   PubMed Web of Science ®Google Scholar
• Lopez M., DiLauro L., Papaldo P. Oral idarubicin in non Hodgkin's lymphomas. Invest New Drugs 1986; 4(3)263–7
   PubMed Web of Science ®Google Scholar
• Gillies H., Liang R., Rogers H., Harper P., Parapia L., Cox G., Johnson S. Phase II trial of idarubicin in patients with advanced lymphoma. Cancer Chemother Pharmacol 1988; 21: 261–4
   PubMed Web of Science ®Google Scholar
• Case D.C., Hayes D.M., Gerber M., Gams R., Ervin T.J., Dorsk B.M. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Cancer Res 1990; 50(21)6833–5
   PubMed Web of Science ®Google Scholar
• Molica S., Levato D., DiRenzo N., La Sala A., Carotenuto M. An “all-oral” combination therapy in chronic lymphocytic leukemia including the oral idarubicin. Am J Hematol 1996; 52(3)235–6
   PubMed Web of Science ®Google Scholar
• Cheson B.D., Bennett J.M., Rai K.R. Guidelines for clinical protocols for chronic lymphocytic leukemia. Recommendations of the National Cancer Institute sponsored working group. Am J Hematol 1989; 29: 152–163
   Web of Science ®Google Scholar